Also trades as: EMMAW (OTC) · $vol 0M
EMMA OTC
Emmaus Life Sciences, Inc.
1W: -18.9%
1M: -22.5%
3M: +381.6%
YTD: +323.1%
1Y: +423.8%
3Y: -72.3%
5Y: -96.3%
$0.06
-0.01 (-15.38%)
Weekly Expected Move ±26.1%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$12M
-25.2% ▼
5Y CAGR: -11.7%
Gross Profit
$12M
-25.0% ▼
5Y CAGR: -11.1%
Operating Income
$231K
+112.2% ▲
Net Income
-$7M
-16.1% ▼
EPS (Diluted)
$-0.12
-20.0% ▼
EBITDA
$231K
+125.4% ▲
5Y CAGR: -49.5%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $21M | $18M | $30M | $17M | $12M |
| YoY Growth | -11.0% | -10.8% | +60.9% | -43.7% | -25.2% |
| Cost of Revenue | $3M | $3M | $1M | $1M | $857K |
| Gross Profit | $17M | $16M | $28M | $15M | $12M |
| Gross Margin | 83.9% | 85.9% | 95.5% | 92.8% | 93.1% |
| R&D Expenses | $4M | $2M | $1M | $657K | $313K |
| SG&A Expenses | $19M | $21M | $24M | $17M | $11M |
| Operating Expenses | $23M | $22M | $25M | $17M | $11M |
| Operating Income | -$6M | -$7M | $4M | -$2M | $231K |
| Operating Margin | -29.7% | -35.8% | 12.0% | -11.4% | 1.9% |
| Interest Expense | $3M | $5M | $7M | $5M | -$7M |
| Income Before Tax | -$16M | -$11M | -$4M | -$6M | -$7M |
| Tax Expense | $25K | $60K | -$59K | $29K | $9K |
| Net Income | -$16M | -$11M | -$4M | -$6M | -$7M |
| Net Margin | -77.4% | -57.8% | -12.6% | -38.7% | -60.2% |
| EPS (Diluted) | $-0.32 | $-0.21 | $-0.07 | $-0.10 | $-0.12 |
| EBITDA | -$13M | -$5M | $4M | -$910K | $231K |
| Shares Outstanding | 49M | 49M | 53M | 63M | 64M |